360 related articles for article (PubMed ID: 25363007)
1. Antiangiogenic therapies for glioblastoma.
Arrillaga-Romany I; Norden AD
CNS Oncol; 2014; 3(5):349-58. PubMed ID: 25363007
[TBL] [Abstract][Full Text] [Related]
2. The future of antiangiogenic treatment in glioblastoma.
Chinot OL; Reardon DA
Curr Opin Neurol; 2014 Dec; 27(6):675-82. PubMed ID: 25313693
[TBL] [Abstract][Full Text] [Related]
3. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
[TBL] [Abstract][Full Text] [Related]
4. Current status of antiangiogenic therapies for glioblastomas.
Arrillaga-Romany I; Reardon DA; Wen PY
Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
[TBL] [Abstract][Full Text] [Related]
5. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl K; Weller M
Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
[TBL] [Abstract][Full Text] [Related]
6. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
Wang N; Jain RK; Batchelor TT
Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy for glioblastoma: current status and future prospects.
Batchelor TT; Reardon DA; de Groot JF; Wick W; Weller M
Clin Cancer Res; 2014 Nov; 20(22):5612-9. PubMed ID: 25398844
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy of brain tumors: the role of bevacizumab.
Trevisan E; Bertero L; Bosa C; Magistrello M; Pellerino A; Rudà R; Soffietti R
Neurol Sci; 2014 Apr; 35(4):507-14. PubMed ID: 24442487
[TBL] [Abstract][Full Text] [Related]
12. Resistance to antiangiogenic therapy.
Weathers SP; de Groot J
Curr Neurol Neurosci Rep; 2014 May; 14(5):443. PubMed ID: 24652451
[TBL] [Abstract][Full Text] [Related]
13. [Anti-angiogenic strategies in glioblastoma].
Guillamo JS
Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
Castro BA; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E9. PubMed ID: 25581938
[TBL] [Abstract][Full Text] [Related]
15. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
[TBL] [Abstract][Full Text] [Related]
17. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
18. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Omar AI
J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.
Lombardi G; Pambuku A; Bellu L; Farina M; Della Puppa A; Denaro L; Zagonel V
Crit Rev Oncol Hematol; 2017 Mar; 111():94-102. PubMed ID: 28259301
[TBL] [Abstract][Full Text] [Related]
20. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
